1366295-76-2

Upstream product

• 1366068-54-3 2-hydroxy-1-(2-(trifluoromethyl)pyrrolidin-1-yl)ethanone 
• 1366295-99-9 3-(3-{2-[(E)-3,5-diamino-6-chloropyrazine-2-carbonylimino]-1,3,8-triazaspiro[4.5]decane-8-carbonyl}benzenesulfonylamino)propionic acid 
• 109074-67-1 (±)-2-(trifluoromethyl)pyrrolidine 
• 1366295-97-7 3-(3-{2-[(E)-3,5-diamino-6-chloropyrazine-2-carbonylimino]-1,3,8-triazaspiro[4.5]decane-8-carbonyl}benzenesulfonylamino)propionic acid tert-butyl ester 

Relevant academic research and scientific papers

PYRAZINE DERIVATIVES AS ENAC BLOCKERS

Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

PYRAZINE DERIVATIVES AS ENAC BLOCKERS

Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.